世界主要先進国における救命・集中治療市場（～2020）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Albumin in Critical Care 9
2.1.1 Overview 9
2.1.2 Diseases or Conditions Indicated for Albumin 9
2.1.3 Epidemiology 10
2.1.4 Other Treatment Options 10
2.1.5 Treatment Patterns 10
2.2 Anti-Thrombin III Concentrates in Critical Care 11
2.2.1 Overview 11
2.2.2 Anti-Thrombin Deficiencies 11
2.2.3 Epidemiology 11
2.2.4 Treatment Options 12
2.2.5 Treatment Patterns 12
2.3 Factor XIII Concentrates in Critical Care 12
2.3.1 Overview 12
2.3.2 FXIII Deficiencies 13
2.3.3 Epidemiology 13
2.3.4 Treatment Options 13
2.3.5 Treatment Patterns 13
2.4 Fibrinogen Concentrates in Critical Care 14
2.4.1 Overview 14
2.4.2 Fibrinogen Deficiencies 14
2.4.3 Epidemiology 15
2.4.4 Treatment Options 15
2.4.5 Treatment Patterns 15
2.5 Prothrombin Complex Concentrate in Critical Care 16
2.5.1 Overview 16
2.5.2 Diseases or Conditions Indicated for Prothrombin Complex Concentrate 16
2.5.3 Epidemiology 17
2.5.4 Treatment Options 17
2.5.5 Treatment Patterns 18
3 Therapeutic Landscape 19
3.1 Albumin Products 19
3.1.1 Buminate (albumin, human) – Baxter 19
3.1.2 Zenalb (human albumin) – Bio Products Laboratory 19
3.1.3 Human Albumin Biotest (albumin, human) – Biotest 19
3.1.4 AlbuRx (albumin) – CSL Behring 19
3.1.5 Albuminar (albumin, human) 5% – CSL Behring 20
3.1.6 Albutein (albumin (human)) – Grifols 20
3.1.7 Albuked (human albumin) – Kedrion 20
3.1.8 Vialebex (human albumin) – French Fractionation and Biotechnology Laboratory 21
3.1.9 Albunorm (human albumin) – Octapharma 21
3.1.10 Alburaas (human albumin) – Shanghai RAAS 21
3.2 Anti-Thrombin Concentrates 21
3.2.1 Atryn (antithrombin alfa) – rEVO Biologics 21
3.2.2 Thrombate III (AT III human) – Grifols 23
3.2.3 Anbinex (AT III human) – Grifols 23
3.2.4 Kybernin P (AT III human) – CSL Behring 23
3.2.5 Aclotine (AT III, human) – French Fractionation and Biotechnology Laboratory 24
3.2.6 Anti-Thrombin III (AT III human) – Baxter 24
3.2.7 AT III Kedrion (AT III human) – Kedrion 24
3.2.8 Neuart (AT III, human) – Mitsubishi Tanabe 24
3.3 Factor XIII Concentrates 25
3.3.1 Fibrogammin/Corifact (factor XIII) – CSL Behring 25
3.3.2 NovoThirteen/Tretten (catridecacog) – Novo Nordisk 25
3.4 Fibrinogen Concentrates 26
3.4.1 Haemocomplettan P/Riastap (fibrinogen concentrate, human) – CSL Behring 26
3.4.2 Clottafact/Clottagen (fibrinogen concentrate, human) – French Fractionation and Biotechnology Laboratory 27
3.4.3 Other Marketed Fibrinogen Concentrates 27
3.5 Prothrombin Complex Concentrates 27
3.5.1 Beriplex P/N/Confidex/Kcentra (Prothrombin Complex Concentrate [Human]) – CSL Behring 27
3.5.2 Bebulin VH (factor IX complex, vapor heated) – Baxter 27
3.5.3 Cofact (prothrombin complex concentrate) – Sanquin 28
3.5.4 Octaplex 500 (human prothrombin complex) – Octapharma 28
3.5.5 Profilnine SD – Grifols 28
3.5.6 Uman Complex DI – Kedrion 28
4 Pipeline for Critical Care Market 29
4.1 Overview of Pipeline 29
4.2 Promising Pipeline Candidates 30
4.2.1 Octaplex 500 (human prothrombin complex) – Octapharma 30
4.2.2 KW-3357– Kyowa Hakko Kirin 30
4.2.3 Human AT Concentrate – Grifols 30
5 Critical Care Market Forecast to 2020 31
5.1 Geographical Markets 31
5.1.1 Major Developed Markets 31
5.1.2 US 34
5.1.3 Top Five European Countries 36
5.1.4 Japan 40
5.1.5 Canada 42
5.2 Drivers and Barriers 44
5.2.1 Drivers 44
5.2.2 Barriers 45
6 Deals and Strategic Consolidations 47
6.1 Major Deals 47
6.1.1 Octapharma Enters Into an Agreement with Pfizer 47
6.1.2 Grifols to Acquire Blood Transfusion Diagnostics Business from Novartis 47
6.1.3 Shin Poong Pharmaceutical and French Fractionation and Biotechnology Laboratory form a Korea-based Bio-pharmaceutical Joint Venture 47
6.1.4 Bain Capital Acquires 80% Stake in Plasma Resources UK 47
6.1.5 Biomat Acquires Three Plasma Donation Centers from Cangene 48
6.1.6 BioRx Enters into Co-Marketing Agreement with CSL Behring for Corifact 48
6.1.7 Baxter Announces Collaboration with Sanquin to Expand Capacity for Plasma Therapies 48
6.1.8 Shire Enters into Licensing Agreement with Sangamo BioSciences 48
6.1.9 Baxter Completes Acquisition of Rights to OBI-1 and Related Assets from Ipsen and Inspiration Biopharma 48
7 Critical Care Market to 2020 – Appendix 50
7.1 Abbreviations 50
7.2 References 51
7.3 Pipeline Products 54
7.4 Market Forecasts to 2020 55
7.4.1 Major Developed Markets 55
7.4.2 US 56
7.4.3 UK 58
7.4.4 France 59
7.4.5 Germany 61
7.4.6 Italy 62
7.4.7 Spain 64
7.4.8 Japan 65
7.4.9 Canada 67
7.5 Research Methodology 68
7.5.1 Coverage 68
7.5.2 Secondary Research 69
7.5.3 Primary Research 69
7.5.4 Therapeutic Landscape 69
7.5.5 Geographical Landscape 71
7.5.6 Pipeline Analysis 72
7.6 Expert Panel Validation 72
7.7 Contact Us 72
7.8 Disclaimer 72